Clinical Trial

Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate the Safety and Tolerability of a Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to an Approved Systemic mRNA Vaccine in Previously Vaccinated Adults
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-08; most recent amendment 2026-07-20.
Status change: Recruiting → Active, Not Recruiting 2026-07-20
Status change: Not Yet Recruiting → Recruiting 2025-11-04
Trial Details
NCT Number NCT07215520
Lead Sponsor CastleVax Inc.
Conditions COVID-19
Enrollment 200 participants
Start Date 2025-11-03
Primary Completion 2026-09-06 (estimated)
Study Completion 2026-09-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-22